Thermo Fisher Scientific Opens Flagship U.S. Bioprocess Design Center to Accelerate Biologics Development
核心洞察
Thermo Fisher Scientific (搜索) opened its flagship U.S. Bioprocess Design Center at its Plainville, Massachusetts facility, adding 4,000 square feet of laboratory and training space dedicated to biologics (搜索) development.
The center provides end-to-end bioproduction workflow solutions including media, cell line development, single-use systems, chromatography, and analytics to help customers accelerate process development for vaccines (搜索) and cell and gene therapies (搜索).
Onsite bioprocess specialists offer hands-on demonstrations, training, and technical consulting to help customers move from development to scalable production with greater speed and confidence.
Thermo Fisher Scientific (搜索) Inc. has opened its flagship U.S. Bioprocess Design Center (BDC) at the company's Plainville, Massachusetts site, expanding the facility to support customers in developing and scaling biologics (搜索). The new center brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faster.
Advanced Bioproduction Capabilities
The BDC features 4,000 square feet of laboratory and training space to support customers in developing biologics (搜索), including vaccines (搜索) and cell and gene therapies (搜索). Customers will experience Thermo Fisher's complete, end-to-end bioproduction workflow of integrated, scalable solutions including media, cell line development, single-use systems, chromatography, filtration, purification and analytics that can unlock productivity gains and reduce time to market.
Onsite bioprocess specialists provide hands-on demonstrations, training and technical consulting. Experts work directly with customers to test and refine processes, validate concepts and address complex challenges to help them move from development to scalable production with greater speed and confidence.
"Our new Bioprocess Design Center brings together Thermo Fisher's experts and customers to tackle some of the most complex challenges in bioprocessing, demonstrating how collaboration and shared innovation can accelerate therapeutic development and help deliver life-changing therapies to patients faster," said Daniella Cramp, senior vice president and president, BioProduction and Customer Excellence at Thermo Fisher Scientific (搜索).
Strategic Facility Expansion
The strategic addition of the BDC to Thermo Fisher's 290,000-square-foot Plainville facility introduces bioproduction capabilities that complement its existing integrated sterile fill-finish and viral vector services and demonstrates the company's comprehensive expertise across the drug development continuum. Located in the greater Massachusetts life science ecosystem, the center is well-positioned for customer collaboration across the U.S., with a shared goal of bringing innovative treatments and hope to patients.
Customers gain a critical advantage in later stages of drug development when they optimize their bioproduction workflows to reduce risk and improve scalability. With Thermo Fisher as a partner, they can carry that momentum forward through preclinical development, clinical research, clinical trials, manufacturing and commercialization through the company's Accelerator™ Drug Development services, which offers end-to-end Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services across all major drug modalities and therapeutic areas.
Massachusetts Life Sciences Leadership
"Companies like Thermo Fisher Scientific (搜索) are choosing Massachusetts because of our world-renowned life sciences sector, and we are proud to partner with them as they continue to grow and invest in our state," said Governor Maura Healey. "This new Bioprocess Design Center will accelerate cutting-edge research, strengthen our economy, and create new jobs for workers across our state. Massachusetts continues to lead the nation in life sciences because we invest in innovation, support our workforce, and partner with companies that are delivering the next generation of life-saving therapies."
"This new Bioprocess Design Center is a strong example of why Massachusetts continues to lead in life sciences," said Massachusetts Economic Development Secretary Eric Paley. "We are fortunate to have an ecosystem where companies like Thermo Fisher can bring together cutting-edge technology, world-class talent, and close collaboration to move breakthrough therapies from concept to production."
Thermo Fisher Scientific (搜索), with annual revenue over $45 billion, already operates bioprocess design centers in China, Korea, Singapore, and India. As of February, the company had 3,500 employees in Massachusetts and is the most valuable publicly traded company in the state.